Ats Corporation · TSX:ATS
Ats — Q2 2027 Earnings Presentation
15 slides from Ats's earnings presentation, Nov 4, 2026
Slide 1: Q2 2027 Earnings Call
Q2 2027 Earnings Call November 4, 2026 8:30am ET
Slide 2: Today's Hosts
Today's Hosts Doug Wright Anne Cybulski Chief Executive Officer Interim Chief Financial Officer 2
Slide 3: Forward Looking Statements
Forward Looking Statements Note to Reader: This presentation and the oral statements made during this call contain certain statements that may constitute forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities laws ("forward-l
Slide 4: Non-IFRS and Other Financial Measures
Non-IFRS and Other Financial Measures Throughout this presentation management uses certain non-IFRS financial measures, non-IFRS ratios and supplementary financial measures to evaluate the performance of the Company. The terms “EBITDA”, "adjusted revenues", “organic revenue”, “adjusted net income”,
Slide 5: Q2 2027 & Recent Highlights
Q2 2027 & Recent Highlights • Q2 Order Bookings¹ of $827M up 13% y/y, resulting in the highest Life Sciences Order Backlog in ATS' history • Order Backlog1 of $2,009M up 6% sequentially ▪ Q2 revenues down 9% y/y to $665.8M, within guided range ▪ Q2 Adj. Earnings from Operations¹ of $57.4M; 8.6% adju
Slide 6: Outlook
Outlook Order Backlog1 well diversified across highly regulated markets: • Life Sciences $1,238M: ◦ Funnel remains strong and diversified across pharmaceuticals, radiopharmaceuticals, medical devices and other applications • Food and Beverage $223M: ◦ Funnel remains strong; opportunities across core
Slide 7: Financial Results
Financial Results Y/Y Y/Y Y/Y Y/Y Q2 Q2 (C$ M, except per share data) Change Change F2027 F2026 Change Change F2027 F2026 ($) (%) ($) (%) Revenue Growth: QTR YTD Revenues $665.8 $728.5 $(62.7) (8.6)% $1,359.5 $1,465.2 $(105.7) (7.2)% Organic1 (9.1) % (7.7) % FX 0.5 % 0.8 % Adjusted revenues1 665.8 7
Slide 8: Summary
Summary ▪ Diversified Order Backlog1 of $2.0 billion supports near-term execution, while differentiated capabilities and structural market drivers underpin attractive growth opportunities ▪ Fixed Cost Transformation Program expected to deliver approximately $65M to $75M of annualized cost savings on
Slide 9: ATS
ATS
Slide 10: WATS
WATS
Slide 11: Appendix: Measures
Appendix Reconciliation of Non-IFRS Measures to IFRS Measures 11
Slide 12: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures The following table reconciles adjusted EBITDA and EBITDA to the most directly comparable IFRS measure (net income) (in millions of dollars): The following table reconciles organic revenue to adjusted revenues, which have been reconciled
Slide 13: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures The following table reconciles adjusted earnings from operations to the most The following table reconciles adjusted basic earnings per share to the most directly comparable IFRS measures (net income (loss)) (in millions of dollars): dir
Slide 14: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures The following table reconciles net debt to adjusted EBITDA to the most directly The following table reconciles free cash flow to the most directly comparable comparable IFRS measure (in millions of dollars): IFRS measure (in millions of
Slide 15: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures
Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures The following table reconciles the previously reported non-IFRS financial measures to reflect the exclusion of the stock-based compensation revaluation expenses: Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 (C$ M) F2025 F2025 F2026 F2026 F2026 F2026 F2027 F2